؉ B cells in vivo, these cells apoptose spontaneously in vitro. The effect of CD5 ligation on apoptosis was studied in 27 newly diagnosed patients with B-CLL, in relation to the expression of surface IgM (sIgM), CD79b, CD38, CD72 and CD19. B cells from 15 patients (group I) were resistant to anti-CD5-induced apoptosis, whereas apoptosis above spontaneous levels was seen in the remaining 12 studied (group II). Group II was then subdivided on the basis of differences in the time required to reach maximum apoptosis: whilst B cells from seven patients underwent apoptosis by 18 h, those from the remaining five needed 36 h to apoptose. The expression of sIgM, CD5, CD79b and CD38 was higher in group II than group I, suggesting that signaling for apoptosis might operate via CD79, and that CD38 expression was required. As shown by flow cytometry and confirmed by Western blotting, apoptosis was associated with a decrease in the ratios of Bcl-2/Bax and Bcl XL /Bax, due to an increase in the level of Bax, but no change in that of Bcl-2. This heterogeneous apoptotic response to CD5 ligation offers an explanation for the incomplete success of anti-CD5 monoclonal therapy, and might help identify patients who would respond to such treatment. Leukemia (2002) 16, 44-52.
Introduction
A number of new therapies for B chronic lymphocytic leukemia (B-CLL) are emerging, 1 and numerous clinical and biological parameters have been reported to correlate significantly with survival. 2 However, due to the marked heterogeneity of this leukemia, prediction of an individual patient's prognosis remains difficult. Definition of patient groups with common prognostic factor is therefore still of major concern for investigators in this field. 3 B cell production is not offset by a commensurate amount of cell destruction in B-CLL. A goal for most therapeutic strategies is, therefore, the induction of apoptosis in malignant cells, but patients often become resistant to many of these drugs. Thus, improvement of apoptosis through immmunotherapy would be of considerable value in the management of B-CLL. 4, 5 Indeed, not only are the tumor cells in these patients resistant to apoptosis, 6 but defects in their programmed cell death (PCD) contribute to the failure to attain complete remission. 7 In sharp contrast to that observed in vivo, leukemic B cells undergo rapid PCD in culture, 8 and this has been profitable for studies on B-CLL apoptosis.
B cells from the vast majority of B-CLL patients express CD5, as well as most of the surface molecules of mature B lymphocytes (reviewed in Ref. 9 ). The density of surface IgM Correspondence: P Youinou, Laboratory of Immunology, Brest University Medical School Hospital, BP 824, F29 609 Brest Cedex, France; Fax: 33-298-22-38-47 Received (sIgM) is, however, abnormally low, whereas that of CD5 is abnormally high. On the other hand, CD72, which represents one of several ligands for CD5, is constitutively and always expressed in B-CLL cells.
More interestingly, CD38 expression, 10 and a high frequency of IgM heavy chain V gene mutations, 11 delineate two groups of patients, with poor and favorable prognosis respectively. Combination of both features provides an even more accurate prognostic indicator. 12 B cells from B-CLL patients are also heterogenous in the expression of CD79. This heterodimer, consisting of Ig␣ (CD79a) and Ig␤ (CD79b), belongs to the B cell receptor (BCR) complex, and regulates the membrane expression of IgM. It appears to be markedly reduced or even undetectable in B cells from 75 to 95% of B-CLL patients. 13, 14 This results from either mutations, insertions or deletions, 15 and/or from alternative splicing of the messenger RNA, 16 with a truncated version expressed mostly in B-CLL patients. The control of signaling via BCR cross-linking relies on the interplay of a number of accessory molecules. For example, it has been shown from immunoprecipitation 17 and co-capping studies 18 that CD5 is part of the BCR, and furthermore, suggested to modulate signaling. 19 In the present study, we have investigated the effect of CD5 ligation on B-CLL B cells apoptosis in vitro, and demonstrated that malignant lymphocytes from the patients were heterogeneous in their susceptibility to CD5-mediated apoptosis. This was seen in just under one-half of the patients studied, and limited to those patients whose B cells expressed CD38 and had a relatively high percentage of CD79b + B cells. Expression of CD38 has been suggested in other studies to relate to a poor prognosis. 10 Our finding, taken together with other prognosis indicators, might provide a strategy for the selective killing of tumor cells in vivo.
Materials and methods

Patients
Twenty-seven previously untreated patients were enrolled in the study, after informed consent was obtained. They all fulfilled the phenotypic criteria for the diagnosis of B-CLL, 20 and were categorized according to Binet's classification. 21 Of these, 20 were scored grade A, three scored grade B, and four scored grade C. There were 16 males and 11 females, ranging in age from 53 to 86 years. The blood count varied from 9.3 to 195.0 × 10 3 lymphocytes per ml, of which 77 to 99% of B cells expressed CD5. Blood was also obtained from five healthy volunteers. All these samples were processed immediately.
Antibodies and reagents
For in vitro stimulation of the cells, two monoclonal antibodies (mAb) were used: F(ab′) 2 
Cell culture
Blood was collected into preservative-free heparin, and the mononuclear cells (MNC) separated by Ficoll-Hypaque (Eurobio, Les Ulis, France) density gradient centrifugation. MNC were treated with a mixture of unconjugated anti-CD3, anti-CD4, anti-CD8 and anti-CD56 mAb, and the B-CLL B cells purified by negative selection using immunomagnetic BioMag goat anti-mouse IgG Ab-coated beads according to the manufacturer's guidelines (BioAdvance, Emerainville, France). This procedure yielded cell populations containing more than 95% B lymphocytes, and virtually no residual T lymphocytes, as established by FITC-anti-CD19 and PE-anti-CD3 staining. Control B cells were enriched from donors' MNC by two cycles of E-rosetting, and purified B cells prepared as described above.
B cells were cultured in 96-well plates (Nunc, Roskilde, Denmark) at 5 × 10 5 cells per well in a final volume of 0.2 ml in RPMI 1640 medium supplemented with 10% fetal calf serum, 2mm l-glutamine, 200 U/ml penicillin, 100 g/ml streptomycin and 15 g/ml gentamycin. Half of the wells were pre-coated for 12 h at 4°C with 50 g/ml of sheep F(ab′) 2 antimouse F(ab′) 2 IgG. The lymphocytes were then cultured at 37°C in a 5% CO 2 incubator with or without F(ab′) 2 anti-CD5 added at the onset of the culture in the cross-linking F(ab′) 2 anti-F(ab′) 2 -coated wells.
Flow cytometry
All Ab were utilized at optimal concentrations for staining, as defined in preliminary experiments. B-CLL cells were washed and resuspended in phosphate-buffered saline (PBS). They Leukemia were stained with appropriate mAb for 30 min on ice and washed three times in PBS supplemented with 2% bovine serum albumin and 0.1% sodium azide. For analysis on an EPICS Elite flow cytometer (Coulter, Hialeh, FL, USA), cells were gated on forward and side scatter to eliminate unwanted debris, and at least 10 000 events were enumerated.
The percentages of positive cells and mean fluorescence intensities (MFI) were compared with isotype controls in all experiments. The numbers of molecules per cell were indirectly quantified by determining the amount of Ab binding to the cells at previously determined saturating concentrations, using the Quantum Simply Cellular kit (Flow Cytometry Standards Corp, San Juan, PR). According to the manufacturer's instructions, 50 l of microbeads were added to 20 l of Ab. Ab binding capacities were derived from the MFI, and expressed as arbitrary units. The production of Bcl-2, Bax and Bcl XL was evaluated in fresh or cultured cells. These were permeabilized with 1 ml of cold methanol 70% and incubated for 1 h at room temperature, centrifuged and washed in PBS. Then, 10 6 B cells were incubated with FITCanti-Bcl-2 or unconjugated anti-Bax or anti-Bcl XL Ab. After another three washes, anti-Bax and anti-Bcl XL binding was developed with FITC-goat F(ab′) 2 anti-rabbit IgG. The levels of these proteins were determined by MFI, and the results expressed as ratios of Bcl-2 and Bcl XL to Bax. An irrelevant FITC-sheep F(ab′) 2 was used as a negative control.
Immunoprecipitation, electrophoresis and Western blotting
The concentration of detergent B cell extracts obtained using Triton X-100 (in 20 mm Tris-Hcl, pH 7.5, 140 mm NaCl, 1 mm EDTA and 1 mm PMSF) before and after stimulation with anti-CD5 F(ab′) 2 was determined by the micro BCA protein assay reagent kit (Pierce, Rockford, IL, USA). Five g of proteins were separated on 15% polyacrylamide gel with sodium dodecyl sulfate, and electroeluted to PVDF sheets (Amersham, Arlington Heights, IL, USA). The strips were blocked overnight using 5% nonfat dry milk in PBS, probed with unconjugated anti-Bcl-2 mAb, or unconjugated rabbit anti-Bax or anti-Bcl XL polyclonal Abs, and revealed by horseradish-peroxidaselabeled anti-mouse or anti-rabbit Abs (Amersham), followed by enhanced chemoluminescence.
Determination of apoptosis Annexin V staining:
B-CLL cells were cultured in the absence or in the presence of cross-linked anti-CD5 F(ab′) 2 , and stained with FITC-coupled annexin V (Beckman Coulter) and propidium iodide (PI). Following a 10-min incubation in the dark, they were analyzed by flow cytometry. Cells that were in the early stages of apoptosis were those positive for annexin V-FITC, but not stained with PI. In selected experiments, the data were expressed as the percentage increase in anti-CD5-induced apoptosis relative to spontaneous apoptosis: (percentage of annexin V+ cells treated with anti-CD5 − percentage of annexin V+ cells incubated in medium)/(percentage of annexinV+ cells incubated in medium) × 100.
Nuclear condensation (confocal microscopy):
The nuclei of B-CLL cells were examined by scanning confocal Leukemia microscopy. B cells were lysed in 0.15% NP40 and 1 mm PMSF buffer for 30 min at 4°C, and nuclei pelleted, resuspended in 0.2 mm HCl, 0.4 mm CaCl 2 , and rotated for 18 h at 4°C. They were resuspended in 50 l 100 mm TRIS, 5 mm NaCl, 0.5 mm CaCl 2 , pH 8.3, and mixed 1:1 with 10 g/ml PI. Confocal laser microscopy was then performed using a Leica TCS 4D (Leica Lasertechnik, Heidelberg, Germany). A focal series of horizontal planes of a section were monitored using a double-dichroic mirror for the excitation beam and a long-pass barrier filter Ͼ580 nm for PI detection using a red-sensitive photomultiplier tube.
Hypoploidy:
B-CLL cells were washed in citrate buffer (0.1 m sodium citrate supplemented with 0.1% Triton X-100), and incubated in 250 l citrate buffer containing 10 g/ml PI overnight at 4°C in the dark. Reduction in PI staining intensity compared with control cells was taken as a measure of hypoploidy.
Statistical analysis
Results were expressed as mean ± s.e.m. Comparisons were made using the chi-squared test (with Yates' correction when required), the paired Wilcoxon's test and the Mann-Whitney U test for unpaired data. Data were analyzed for correlations using the Spearman's rank test.
Results
CD5-induced apoptosis in B chronic lymphocytic leukemia
B-CLL cells were cultured in medium alone, or in the presence of 10 g/ml anti-CD5 F(ab′) 2 , and aliquots of cells harvested after 18, 36 and 72 h in culture. CD5-induced apoptosis was compared to spontaneous apoptosis. Annexin V-binding clearly defined two groups of patients ( Figure 1 ). Fifteen of
Figure 1
Spontaneous and anti-CD5-induced apoptosis in B cells from patients with B-CLL. Freshly isolated B-CLL cells were cultured for 18, 36 or 72 h in the absence (open bars) or in the presence (filled bars) of 10 g/ml anti-CD5 monoclonal antibody. Apoptosis was quantified by the binding of FITC-annexin V to the propidium iodide-negative cells. Two groups of patients were identified: 15 were resistant to anti-CD5-triggered apoptosis (group I), while 12 were not (group II). A further division of group II was made, according to the time taken for CD5-induced apoptosis to occur: subgroup IIa ('early apoptosis', n = 7) and subgroup IIb ('late apoptosis', n = 5). The results of triplicate assays were averaged. Means and s.e.m. are shown. them (group I) were resistant to CD5 ligation, as shown by their similarity to spontaneous apoptosis: 11.5 ± 1.2%, compared with 11.0 ± 1.1% after 18 h; 19.9 ± 1.7%, compared with 19.2 ± 1.6% after 36 h; and 32.4 ± 1.9%, compared with 34.8 ± 1.9% after 72 h in culture. In contrast, B cells from the remaining 12 patients (group II) exhibited significantly higher percentages of annexin V binding in response to CD5-crosslinking, compared with spontaneous levels: 22.1 ± 2.9 vs 11.8 ± 1.3% after 18 h (P Ͻ 0.02); 49.0 ± 4.6 vs 23.1 ± 2.5% after 36 h (P Ͻ 0.001); and 72.7 ± 3.4 vs 35.2 ± 3.8% after 72 h in culture (P Ͻ 0.001).
Detailed analysis of group II patients allowed their further division into two subgroups, according to the time taken for apoptosis to occur. In seven patients (subgroup IIa), the percentages of annexin V-positive cells were increased as early as 18 h in culture (28.7 ± 1.7 vs 11.6 ± 1.6%, P Ͻ 0.02), and this augmentation was even more pronounced after 36 h (52.2 ± 1.7 vs 20.2 ± 1.6%, P Ͻ 0.02), and after 72 h in culture (74.7 ± 2.0 vs 30.6 ± 1.7%, P Ͻ 0.02). In the remaining five patients (subgroup IIb), apoptosis occurred later, so that differences became significant only after 36 h (46.9 ± 5.8 vs 27.0 ± 2.1%, P Ͻ 0.04), and 72 h in culture (69.8 ± 3.5 vs 41.6 ± 4.1%, P Ͻ 0.04). Importantly, the levels of CD5-induced apoptosis did not correlate with those of spontaneous apoptosis in group II patients, either at 18 h (P = 0.19), or at 36 h (P = 0.17) and 72 h (P = 0.20), suggesting that the level of base line PCD had no influence on that of CD5-induced apoptosis. Thus, no differences in spontaneous apoptosis were seen between group I and group II patients.
Increases in annexin V-binding were induced by anti-CD5 over spontaneous apoptosis: 5.5 ± 3.4, 4.3 ± 1.8 and −1.7 ± 1.4% after 18, 36 and 72 h in culture, respectively, for group I patients; 200.8 ± 61.8, 199.8 ± 56.8 and 156.8 ± 21.6% after 18, 36 and 72 h in culture, respectively, for subgroup IIa patients; and 10.9 ± 6.0, 69.8 ± 27.3 and 79.7 ± 18.1% after 18, 36 and 72 h in culture, respectively, for subgroup IIb patients.
Confirmation experiments
To confirm that the delay in apoptosis seen in subgroup IIb was not related to the dose of anti-CD5 mAb added rather than the culture duration, B-CLL cells from three group I, three 
Figure 3
Anti-CD5-mediated apoptosis of B-CLL cells confirmed using different assays. Representative examples are shown. Freshly isolated B-CLL cells from five group I (a, c, e) and five subgroup IIa unselected patients (b, d, e) were incubated with 10 g/ml anti-CD5 monoclonal antibody for 18 (a-d) or 24 h (e, f) . B cells were double-stained with annexin V-FITC and propidium iodide (PI), and analyzed by flow cytometry (a, b). Nuclei were stained with PI and analyzed by confocal microscopy (original magnification × 630) to evaluate the chromatin condensation (arrows). Cells were permeabilized with Triton X-100, stained with PI and analyzed by flow cytometry to enumerate hypoploid cells (e, f).
Leukemia subgroup IIa and three subgroup IIb unselected patients were cultured with 1, 5, 10, 20 and 40 g/ml anti-CD5 for 18 h (Figure 2 ). Whereas induction of annexin V binding by anti-CD5 was partially dose-dependent for the B cells of subgroup IIa ('early apoptosis'), no differences in levels of apoptosis were noted for the B cells from subgroup IIb patients ('late apoptosis') or group I patients (no CD5-triggered apoptosis).
Two other methods for measuring apoptosis were used to confirm the annexin V data. B cells treated with anti-CD5 from five group I and five subgroup IIa unselected patients were analyzed using measurement of nuclear condensation and hypoploidy. Representative examples are shown in Figure 3 . After cross-linking with anti-CD5, the number of FITC-annexin V-positive/PI-negative cells increased (compare Figure 3b with Figure 3a) , and confocal microscopy of PIstained nuclei revealed the presence of condensed chromatin (compare Figure 3d with Figure 3c ). Hypoploid cells became detectable following a 24-h incubation period (compare Figure 3f with Figure 3e ).
That the induction of apoptosis was not epitope-dependent was indicated by the similar results obtained using Leu-1 (data not shown) and UCHT2 anti-CD5 mAb which recognize different epitopes of CD5. 22 
Association of CD5-mediated apoptosis with the severity of the disease
CD5-mediated apoptosis was associated with the initial severity of the disease, because there were 14 grade A and one grade B patients in group I, compared with six grade A, two grade B and four grade C patients in group II (P Ͻ 0.04). We were, however, unable to find any correlation of CD5-mediated apoptosis with various clinical parameters, includ-Leukemia ing age, sex, platelet count, hemoglobin concentration and lymph mode involvement.
Relationships between CD5 apoptosis and surface molecules
As one approach to determining why B-CLL B cells from only some patients were sensitive to anti-CD5-mediated apoptosis, we examined the expression of B cell-specific surface molecules which are part of the BCR complex (such as CD5 itself, sIgM and CD79b), or not (such as CD19, CD72 and CD38). The low density of sIgM expressed by B-CLL cells compared with control cells (Table 1) , was significantly higher in group II than group I patients (33.2 ± 4.0 vs 11.9 ± 1.1 × 10 3 molecules per cell, P Ͻ 0.0001), and in subgroup IIa ('early apoptosis') than subgroup IIb ('late apoptosis') patients (39.9 ± 5.4 vs 23.8 ± 0.5 × 10 3 molecules per cell, P Ͻ 0.04). The density of CD5 showed the same trend, and was overexpressed in all patients, but significantly more in group II than group I patients (59.0 ± 5.6 vs 34.8 ± 2.9 × 10 3 molecules per cell, P Ͻ 0.004), while the levels were the same in subgroup IIa and subgroup IIb patients. In contrast, expression of CD72 and CD19 was similarly reduced, compared with the controls, in both groups and subgroups.
Although low compared with the controls (Table 2) , the expression of CD79b, as determined by the number of positive cells, was also higher in group II than in group I patients (15.6 ± 1.9 vs 6.7 ± 1.5%, P Ͻ 0.002), but identical in subgroups IIa and IIb (15.8 ± 2.4 vs 15.3 ± 3.3%). CD79b and sIgM expression, on a per cell basis, was similar in intensity, and in the 27 patients studied these intensities were directly related (P Ͻ 0.02). Finally, there were more CD38 + B cells in group II than group I patients: 32.0 ± 6.6 vs 8.1 ± 2.1% of the cells (P Ͻ 0.0006), ie, five of 12 cases у30% in group II vs one of 15 in group I (P Ͻ 0.03). This was not seen in subgroup IIa compared with subgroup IIb patients: 32.0 ± 3.6 vs Table 1 Density of membrane CD5, IgM, CD72 and CD19 in B cells from B-CLL patients categorized in relation to their sensitivity to anti-CD5-induced apoptosis through CD5 ligation
Samples
No. of molecules per cell (×10 Groups I and II B-CLL cells were defined as resistant and sensitive, respectively, to anti-CD5-induced apoptosis (see Figure 1) . Numbers of molecules per cell were quantified by determining the amount of antibody binding to the cells, using the Quantum Simply Cellular kit. A total of 27 patients were studied and compared with five control samples. Means ± s.e.m. are presented. NS, not significant. 
Anti-and pro-apoptotic factors
Ratios of the anti-apoptotic molecules Bcl-2 and Bcl XL , relative to the pro-apoptotic molecule Bax, were determined (Table 3) . Group II patients' fresh B cells had higher (P Ͻ 0.04) constitutive Bcl-2/Bax ratios (6.7 ± 0.8) than group I (3.4 ± 0.6), and subgroup IIa (9.0 ± 0.9) higher (P Ͻ 0.01) than subgroup IIb (5.0 ± 0.7). Similar differences were noted for the elevated Bcl XL /Bax ratios in group II as compared with group I, and in subgroup IIa as compared with subgroup IIb patients, but these were not statistically significant. The Bcl XL /Bax ratios were however significantly (P Ͻ 0.04) in subgroup IIa than in group I patients. The levels of the factors were then determined in six group I and six group II unselected patients (four subgroup IIa and two subgroup IIb patients). They remained unchanged after Table 3 Expression of anti-and pro-apoptotic molecules in B cells from patients with B-CLL in relation to sensitivity to apoptosis induced by CD5 ligation
Samples
Ratios of MFI Bcl-2/Bax Bcl XL /Bax
Group I (n = 15) 3.4 ± 0.6 0.4 ± 0.1 Group II (n = 12) 6.7 ± 0.8 0.6 ± 0.1 Difference (I vs II) P Ͻ 0.04 NS Subgroup IIa (n = 7) 9.0 ± 0.9 0.7 ± 0.1 Subgroup IIb (n = 5) 5.0 ± 0.5 0.5 ± 0.1 Difference (IIa vs IIb) P Ͻ 0.01 NS
For the definition of the patient groups and subgroups see the footnote to Table 1 . Production of Bcl-2, Bax and Bcl XL were expressed as mean fluorescence intensities (MFI), and levels of these proteins as the ratios of Bcl-2 and Bcl XL to Bax. Means ± s.e.m. are presented. NS, not significant.
Figure 4
Changes in expression of Bcl-2, Bcl XL and Bax during apoptosis. The expression of Bcl-2 relative to Bax and to Bcl XL was determined in six group I and six group II (four subgroup IIa and two subgroup IIb) unselected patients before (white columns) and after 18 h in culture in the absence (black columns) or in the presence (grey columns) of anti-CD5. The mean fluorescence intensities were determined by flow cytometry (means of triplicate assays), and expressed as ratios of Bcl-2 and Bcl XL to Bax. (*P Ͻ 0.05, values after 18 h in culture, compared with B cells at the onset of the culture.)
18 h in culture in the absence of anti-CD5 (Figure 4 ). By contrast, when anti-CD5 was present, the Bcl-2/Bax and Bcl XL /Bax ratios declined significantly (P Ͻ 0.05) in group II: from 6.7 ± 1.2 to 1.5 ± 0.1, and from 0.6 ± 0.1 to 0.2 ± 0.1, respectively. There were, however, no significant changes in group I patients' B cells: from 3.9 ± 0.6 to 3.8 ± 0.5 for Bcl-2/Bax, and from 0.5 ± 0.1 to 0.6 ± 0.1 for Bcl XL /Bax. While Bcl-2 did not vary during CD5-induced apoptosis in group II patients, there was a concomitant increase in Bax as early as after 18 h in culture (representative examples are shown in Figure 5 ). However, it is noteworthy that the Bcl XL /Bax ratios were similar in group II and in group I ( Table 3) , given that the level
Figure 5
Determination of Bcl-2 and Bax B-CLL B cells at the onset or after 18 or 36 h of culture in the absence or in the presence of anti-CD5. Representative examples of group I and group II patients, one each, are shown. From left to right: isotypic control (white histograms), Bcl-2 (black histograms) and Bax (grey histograms).
Leukemia
of Bcl XL was higher in the former than in the latter patients. Interestingly, after 36 h in culture, in the presence or in the absence of anti-CD5, the level of Bcl-2 declined markedly in group I patients. This protein was moderately reduced in spontaneous apoptosis in group II patients (data not shown), but essentially not different from that seen in CD5-induced apoptosis.
These results were confirmed by Western blot analysis ( Figure 6 ). The level of Bax was markedly augmented in group II patients, while there was indeed a slight increased expression of Bcl XL , following incubation of the cells with anti-CD5 F(ab′) 2 for 18 h. In contrast Bax remained unchanged in group I patients and Bcl XL was slightly augmented in group II.
Discussion
The central finding of this report is that the response to anti-CD5-mediated apoptosis is varied in B-CLL, consistent with the overall heterogeneity of this leukemia. B cells from over one-half of the patients (group I) were resistant to CD5 ligation, whereas others showed anti-CD5-induced apoptosis above that seen in cells cultured alone (group II). In group II patients, the time for CD5-mediated apoptosis of B cells was much less for some patients than others. It has previously been shown that the percentages of CB-CLL cells dying spontaneously in vitro correlated with the clinical stage of the disease. 23 Since in our study anti-CD5-mediated apoptosis was related to disease severity, it was possible that anti-CD5 was enhancing apoptosis only in those with high spontaneous levels of apoptosis. There were, however, no significant differences in spontaneous apoptosis between group I and group II patients' B cells.
The disease outcome in B-CLL patients is still difficult to
Figure 6
Western blot analysis of Bax, Bcl-2 and Bcl XL in B-CLL B cells, freshly explanted or stimulated with anti-CD5 for 18 h. Detergent cell extracts were obtained from B cells and subjected to 15% polyacrylamide gel electrophoresis before and after incubation with anti-CD5 F(ab′) 2 . Anti-and pro-apoptotic factors were probed with anti-Bcl-2 monoclonal antibody (Ab), or rabbit anti-Bax or anti-Bcl XL polyclonal Abs. These were then revealed by horseradish-peroxidaseconjugated anti-mouse or anti-rabbit Abs, followed by enhanced chemiluminescence.
predict. The National Cancer Institute, 24 and the members of the International Study Group on B-CLL 25 proposed early guidelines for response criteria. 2, 3 New features have since been identified, such as chromosomal abnormalities, 26 expression of CD38, 11 and, together with CD38, IgM V gene mutations. 12 Patients with low levels of CD38, 10 accompanying a high frequency of IgM heavy chain V gene mutations, 11 require minimum therapy and have a prolonged survival, whereas those with higher CD38 expression and fewer mutations respond poorer to multidrug regimens and have a shorter survival time. 12 Our data, based on the sensitivity of the patient's B cells to CD5-mediated apoptosis, are consistent with this classification. Susceptible patients (group II) consistently had higher levels of expression of CD38, and both sIgM and CD5. Furthermore, sIgM, but not CD5, was significantly lower in subgroup IIa than in subgroup IIb patients. Thus, CD38 was a defining phenotype in patients resistant to multidrug treatments, 10, 12 and, here, identified as a population sensitive to the apoptosis-inducing effects of anti-CD5 cross-linking in vitro. It has previously been demonstrated 10 that signals delivered by sIgM activate PCD in CD38
+ , but not in CD38-negative B-CLL cells, although direct ligation of CD38 alone did not induce apoptosis in this study. 10 Our data suggest that CD38 may also be necessary for anti-CD5-mediated apoptosis, but whether it plays an active role in the process remains to be determined. The percentages of CD79b-expressing B cells were also found to be higher in group II patients, compared with group I, raising the possibility that B-CLL cells require significant expression of CD79b to mediate anti-CD5-induced apoptosis. At present, 27 it is unknown whether CD79b is phosphorylated when CD5 is ligated. It is possible that CD5 per se can act as a signaling molecule since it has been shown to possess one immunoreceptor tyrosinebased inhibition motif. 28 In this regard, higher levels of CD5 also correlated with apoptosis observed in group II patients. The meaning of this increased expression is unclear, but could indicate differences in the stages of differentiation of the group II patients' B cells from group I patients, which in turn, might be related indirectly to their susceptibility to apoptosis. Supporting this view is that CD38-negative B cells with mutated IgM V genes characterize post-germinal center (GC) B cells, while unmutated CD38 + B cells display surface markers B cells committed to entering the GC. 29 Alternatively, the patient groups might reflect the existence of two different CD5 + B cell populations, as previously discussed. 30 We have postulated that two discrete kinds of CD5 + B cells co-exist: 'classical' CD5 + B cells located in the cord blood, serous cavities and lamina propria, as opposed to 'induced' CD5 + B cells populating the follicular mantle (FM) and the subepithelial zones of secondary lymphoid organs. Although the normal counterpart of B-CLL B cell is still in dispute, 31 for some B-CLL it is most likely to be the FM cell. 32 Some of our data are consistent with this view, in that they suggest that group II B-CLL cells expressing a CD38-coupled functional BCR, are derived from the FM B cells. The origin of the group I B cells is less clear, but they did not possess the relevant molecule(s) of the BCR complex to be induced into apoptosis. Since ligation of CD5 sustains proliferation of activated tonsilar B cells, 33 but apoptosis is induced when the cells are resting, 34 it is not inconceivable that B cells from group I patients represent partially activated cells ('induced' post-GC CD5 + B cells?), whereas those from group II B-CLL are more related to resting ('classical' pre-GC CD5 + B cells?). Our hypothesis is consistent with the presence of the spliced form of CD79b in group I B cells, because this has been shown to prevail in activated normal B cells. 35, 36 CD5 has recently been endowed with negative effects on B cell signaling, given its association with the src homology 2 domain-containing phosphatase 1 (SHP-1) which is itself connected to the BCR complex. 37 Owing to the higher number of IgM molecules, compared with that of CD5, only a proportion of IgM molecules can associate with CD5, and thereby with SHP-1. This concept is supported by our observation that the B cells from group II patients exhibited more sIgM than group I. In the presence of more sIgM, the probability increases that CD5 associates SHP-1 with the BCR, leading possibly to greater sensitivity to CD5-induced apoptosis.
As an approach to understanding the mechanisms of anti-CD5-induced apoptosis, 38 we studied levels of the antiapoptotic Bcl-2 and Bcl XL molecules relative to the pro-apoptotic Bax. Bcl-2, constitutively present at high levels in B-CLL leukemic cells, did not change during CD5-induced apoptosis in group II patients, whilst there was a concomitant increase in the pro-apoptotic protein Bax. Similar observations have recently been reported in a human B lymphoma cell line 39 and anti-sIgM-induced apoptosis in B-CLL. 40 Although studies with larger numbers of patients are required before firm conclusions cans be reached, CD5-mediated apoptosis appears to involve signaling through the Bcl-2 pathway, like that induced by anti-IgM. The mechanisms of such an induction are still unclear. Studies in B-CLL have indicated that in both spontaneous and drug-induced apoptosis, there is a lack of involvement of caspase-2, but processing of caspase-3 and 8. 41, 42 Recently, survivin, which is a member of a family of inhibitors of apoptosis has also been shown to be a key regulator in this process. 43 The molecular mechanisms of CD5-mediated apoptosis in group II patients are currently under study in our laboratories. Experiments have been designed to address these issues.
In practice, our data suggest that the inducibility of apoptosis, in vitro, by anti-CD5 is a useful prognostic indicator, and now has to be looked at in relation to mutational status of immunoglobulin V genes and the development of drug resistance in B-CLL patients. It also provides a rationale for a potentially novel kind of treatment for B-CLL. Targeting the BCR using the CD5 mAb would be an approach to therapy of group II patients who respond poorly to chemotherapy. Clinical trials of anti-CD5 mAb treatment have already taken place. The response seen in two out of two patients, 44 and two out of 13 patients 45 was transient in early reports. More recently, a persistent response was obtained in five out of 10 patients using a radioimmunoconjugate. 46 Our data support the prediction that patients who respond to anti-CD5 treatment in vivo could be preselected on the basis of apoptosis induced by anti-CD5 treatment of their B cells in vitro.
